Skip to main content

FDA Approvals

Payers' Guide, FDA Approvals

Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death

Payers' Guide, FDA Approvals

Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

Once-Fatal Conditions Have Become Chronic: Early Trends in the FDA’s 2015 Approvals

Gary Branning, MBA

Payers' Guide, FDA Approvals

Glyxambi (Empagliflozin/Linagliptin): A Dual- Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer

Payers' Guide, FDA Approvals

Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma

Lisa A. Raedler, PhD, RPh

Idelalisib Approved for 3 Types of Hematologic Cancers

Page 43 of 53
Results 421 - 430 of 522